摘要
目的探讨非小细胞肺癌(NSCLC)患者程序性细胞死亡1(PD-1)基因单核苷酸多态性与远期生存的关系。方法选择2020年6月至2022年6月义乌市中心医院收治的80例NSCLC患者,采用聚合酶链式反应限制性片段长度多态性检测患者外周血中PD-1.1(rs36084323)及PD-1.5(rs2227981)位点多态性。随访统计NSCLC患者的无进展生存期(PFS)及总生存期(OS)。分析非小细胞肺癌患者PD-1基因型与临床参数的相关性。并采用Cox单因素和多因素分析评估NSCLC患者PFS和OS的影响因素。结果NSCLC患者PD-1.1位点AA、AG、GG基因型占比分别为30.00%、50.00%、20.00%,PD-1.5位点CC、CT、TT基因型患者占比分别为55.00%、38.75%、6.25%,差异均无统计学意义(均P>0.05)。PD-1.1基因型与分化程度有关(P<0.05);PD-1.5基因型与淋巴结转移有关(P<0.05)。PD-1.1位点AA、AG、GG基因型患者中位PFS分别为15.00(95%CI:1.65~28.35)个月、15.00(95%CI:10.53~19.47)个月、11.00(95%CI:5.12~16.88)个月,中位OS分别为30.00(95%CI:23.58~36.42)个月、31.00(95%CI:29.45~32.56)个月、22.00(95%CI:11.56~32.44)个月,三种基因型PFS、OS差异均无统计学意义(均P>0.05)。PD-1.5位点CC、CT+TT基因型患者中位PFS分别为18.00(95%CI:12.47~23.53)个月、10.00(95%CI:6.47~13.53)个月,中位OS分别为32.00(95%CI:29.86~34.14)个月、22.00(95%CI:15.25~28.75)个月,差异均有统计学意义(均P<0.05)。Cox多因素分析结果显示,NSCLC患者临床分期、淋巴结转移、PD-1.5位点基因型是PFS的独立影响因素(均P<0.05);年龄、临床分期、淋巴结转移、PD-1.5位点基因型是OS的独立影响因素(均P<0.05)。结论PD-1.5位点多态性与NSCLC患者远期生存相关,为NSCLC机制研究及靶向治疗提供了新的研究思路。
Objective To explore the relationship between single nucleotide polymorphism of programmed cell death 1(PD-1)gene and long-term survival in non-small cell lung cancer(NSCLC)patients.Methods Eighty NSCLC patients admitted to the Yiwu Central Hospital from June 2020 to June 2022 were selected.Polymerase chain reaction restriction fragment length polymorphism was used to detect the PD-1.1(rs36084323)and PD-1.5(rs2227981)polymorphisms in the peripheral blood of the patients.Follow-up statistics were conducted on the progression free survival(PFS)and overall survival(OS)of NSCLC patients.We also analyzed the correlation between PD-1 genotype and clinical parameters in non-small cell lung cancer patients.And Cox univariate and multivariate analyses were used to evaluate the influencing factors of PFS and OS in NSCLC patients.Results The proportion of PD-1.1 AA,AG,and GG genotypes in NSCLC patients was 30.00%,50.00%,and 20.00%,respectively,while the proportion of PD-1.5 CC,CT,and TT genotypes in NSCLC patients was 55.00%,38.75%,and 6.25%,respectively.The differences were not statistically significant(all P>0.05).PD-1.1 genotype was correlated with differentiation degree(P<0.05);PD-1.5 genotype was associated with lymph node metastasis(P<0.05).The median PFS of patients with PD-1.1 genotype AA,AG,and GG were 15.00(95%CI:1.65-28.35)months,15.00(95%CI:10.53-19.47)months,and 11.00(95%CI:5.12-16.88)months,respectively.The median OS was 30.00(95%CI:23.58-36.42)months,31.00(95%CI:29.45-32.56)months,and 22.00(95%CI:11.56-32.44)months,respectively.There was no statistically significant difference in PFS and OS among the three genotypes(all P>0.05).The median PFS of patients with PD-1.5 locus CC and CT+TT genotypes were 18.00(95%CI:12.47-23.53)months and 10.00(95%CI:6.47-13.53)months,respectively.The median OS was 32.00(95%CI:29.86-34.14)months and 22.00(95%CI:15.25-28.75)months,respectively,and the differences were statistically significant(all P<0.05).The Cox multivariate analysis results showed that clinical stage,lymph node m
作者
吴俊沛
方权
朱晓丹
Wu Junpei;Fang Quan;Zhu Xiaodan(Zhejiang Chinese Medical University,Hangzhou 310053,China;Department of Respiratory Medicine,Yiwu Central Hospital,Yiwu 322000,China;Department of Radiology,Yiwu Central Hospital,Yiwu 322000,China)
出处
《中国医师杂志》
CAS
2024年第4期568-572,576,共6页
Journal of Chinese Physician
基金
义乌市科研计划项目(20-3-027)。
关键词
癌
非小细胞肺
程序性细胞死亡受体1
多态性
单核苷酸
无进展生存期
Carcinoma,non-small-cell lung
Programmed cell death 1 receptor
Polymorphism,single nucleotide
Progression-free survival
